In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2

@article{Liscano2020InSD,
  title={In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2},
  author={Yamil Liscano and Jos{\'e} O{\~n}ate-Garz{\'o}n and Iv{\'a}n Dar{\'i}o Ocampo-Ib{\'a}{\~n}ez},
  journal={Molecules},
  year={2020},
  volume={25}
}
A serious pandemic has been caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The interaction between spike surface viral protein (Sgp) and the angiotensin-converting enzyme 2 (ACE2) cellular receptor is essential to understand the SARS-CoV-2 infectivity and pathogenicity. Currently, no drugs are available to treat the infection caused by this coronavirus and the use of antimicrobial peptides (AMPs) may be a promising alternative therapeutic strategy to control SARS… Expand
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2
TLDR
This review is written based on the literature search using several databases, previous studies, scientific reports, the current knowledge about the antimicrobial peptides (AMPs), and personal analyses on the potential of the antiviral peptides for the treatment of COVID-19. Expand
A Fungal Defensin Targets the SARS−CoV−2 Spike Receptor−Binding Domain
  • Bin Gao, Shunyi Zhu
  • Medicine
  • Journal of fungi
  • 2021
TLDR
The discovery of a naturally occurring fungal defensin from the dermatophytic fungus Microsporum canis with antibacterial activity, and its improvement via a combination of computational and experimental approaches are reported. Expand
In silico Multi Subunit Vaccine Design Referring Spike Glycoprotein of SARS-COV-2 (COVID-19): The World Pandemic
TLDR
In silico immune evaluation using C-ImmSim server showed that the peptide could concurrently elicit cell-mediated and humoral immune responses, and docking results of the multi-epitope vaccine peptide with human leukocyte antigen class I and II alleles predicted efficient binding and the resulted docked models were stable during simulation. Expand
Antimicrobial Peptides: A Potent Alternative to Antibiotics
TLDR
This review focuses on antimicrobial peptides use against ESKAPE bacteria, especially in biofilm treatments, their synergistic activity, and their application as prophylactic agents. Expand

References

SHOWING 1-10 OF 143 REFERENCES
Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction
TLDR
SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells, the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Expand
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
TLDR
EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively. Expand
Peptide-Protein Interaction Studies of Antimicrobial Peptides Targeting Middle East Respiratory Syndrome Coronavirus Spike Protein: An In Silico Approach
TLDR
It is observed that seven putative peptides have good binding score based on cluster size cutoff of 208, which means that seven peptides could serve as a therapeutic option for MERS and enhance its treatment outcome. Expand
Structural basis of receptor recognition by SARS-CoV-2
TLDR
This study determines the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 (engineered to facilitate crystallization) in complex with ACE2 and sheds light on the structural features that increase its binding affinity to ACE2. Expand
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
TLDR
It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry. Expand
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
TLDR
High-resolution crystal structures of the receptor-binding domain of the spike protein of SARS-CoV-2 and SARS -CoV in complex with ACE2 provide insights into the binding mode of these coronaviruses and highlight essential ACE2-interacting residues. Expand
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
TLDR
It is demonstrating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination, and it is shown that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of Sars- coV- 2 S and SARS S bind with similar affinities to human ACE2, correlating with the efficient spread of SATS among humans. Expand
Drug targets for corona virus: A systematic review
TLDR
The occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs, which may serve an important role from drug design perspectives. Expand
MERS-CoV spike protein: a key target for antivirals
TLDR
This review illustrates MERS-CoV S protein’s structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS- coV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expand
In Silico Discovery of Candidate Drugs against Covid-19
TLDR
This study investigated in silico the basic mechanism of ACE2 in the lung and provided evidences for new potentially effective drugs for Covid-19 treatment, and constructed a protein-protein interaction network containing the genes co-expressed with ACE2. Expand
...
1
2
3
4
5
...